• Hear about policies affecting rare diseases in this evolutionary time: the opportunities, challenges and possible solutions
  • Discuss the legislation that, by the time of the meeting, Congress is likely to have enacted, including special provisions applicable to orphan products
  • Learn some of the administrative initiatives that FDA is considering that will affect product development and government reviews
  • Learn strategies on how you can become a more effective advocate

Featured Speakers Include


  • Stephen P. Spielberg, MD, PhD: Deputy Commissioner, Medical Products and Tobacco, Office of the Commissioner, FDA


  • Cole Werble, MA: Founding Member, Prevision Policy, LLC
  • David P. Meeker, MD: President and Chief Executive Officer, Genzyme
  • Charles A. Mohan, Jr.: CEO/Executive Director, The United Mitochondrial Disease Foundation

© 2017